![Bihua Chen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bihua Chen
Directeur/Membre du Conseil chez
BLOSSOMHILL THERAPEUTICS, INC.
Fortune : 70 907 $ au 31/10/2026
Profil
Bihua Chen founded Cormorant Asset Management LP in 2013, where she is working as Chief Executive Officer & Chief Investment Officer from 2013 and Cormorant Asset Management LP in 2013, where she is working as CEO and Portfolio Manager from 2013.
Ms. Chen also currently works at Helix Acquisition Corp.
III, as Chairman & Chief Executive Officer from 2026, Element Science, Inc., as Director, BiVACOR, Inc., as Director, and various other companies.
Ms. Chen also formerly worked at Helix Acquisition Corp., as Chairman & Chief Executive Officer from 2020 to 2022, Helix Acquisition Corp.
II, as Chairman & Chief Executive Officer from 2021 to 2025, Apellis Pharmaceuticals, Inc., as Independent Director, and various other companies.
Ms. Chen received her undergraduate degree in 1990 from Fudan University, graduate degree in 1994 from Weill Cornell Graduate School of Medical Sciences, and Masters Business Admin degree in 1998 from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BIOMEA FUSION INC 0,16% | 22/10/2025 | 110 792 ( 0,16% ) | 70 907 $ | 31/10/2026 |
| 06/08/2026 | 0 ( -.--% ) | - $ | 31/10/2026 |
Postes actifs de Bihua Chen
| Sociétés | Poste | Début |
|---|---|---|
| BLOSSOMHILL THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/02/2021 |
Cormorant Asset Management LP
 Cormorant Asset Management LP Investment ManagersFinance Cormorant’s Hedge Fund seeks superior risk-adjusted returns with low market correlation through a combination of long investment positions and short selling to achieve capital appreciation while attempting to preserve capital and mitigate risk through hedging activities. Most of the Hedge Funds’ assets are invested on a global basis in publicly traded equity securities in the healthcare and life science industries. The Private Equity Funds aim to generate significant long-term capital appreciation by creating or investing in innovative companies in the biotechnology and life sciences marketplace. The firm uses a fundamental, research-intensive approach that focuses primarily on scientific research to identify investment opportunities. | Directeur Général | 01/01/2013 |
Cormorant Asset Management LLC/Private Equity/
 Cormorant Asset Management LLC/Private Equity/ Investment ManagersFinance Cormorant Asset Management/Private Equity/ invests in companies located in the United States. The firm targets companies operating in the fields of life-science and biotech. It provides financing for mezzanine and early stage capital requirements. | Directeur Général | 01/02/2013 |
Atia Vision, Inc.
 Atia Vision, Inc. Medical SpecialtiesHealth Technology Manufactures intraocular lens | Directeur/Membre du Conseil | - |
Chroma Medicine, Inc.
 Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures genetic medicines | Directeur/Membre du Conseil | - |
Orionis Biosciences BV
 Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Operates as a drug discovery and development biotechnology company | Directeur/Membre du Conseil | 29/06/2021 |
Adona Medical, Inc.
 Adona Medical, Inc. Medical SpecialtiesHealth Technology Develops implantable cardiovascular devices | Directeur/Membre du Conseil | - |
Akura Medical, Inc.
 Akura Medical, Inc. Medical SpecialtiesHealth Technology Develops next-generation thrombectomy devices | Directeur/Membre du Conseil | - |
Anciens postes connus de Bihua Chen
| Sociétés | Poste | Fin |
|---|---|---|
| BIOMEA FUSION, INC. | Directeur/Membre du Conseil | 22/07/2025 |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Bihua Chen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
71
Relations au 1er degré
47
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 47 |
|---|---|
RiverSource Investments LLC
 RiverSource Investments LLC Investment ManagersFinance RiverSource Investments combines macroeconomic, geopolitical analysis with fundamental research to identify the most promising investment opportunities across global regions, markets, sectors and stocks. Stocks are selected based on their ability to outperform in the context of the firm's economic outlook. Stocks are sold when there is a change in their fundamental characteristics and when they are no longer expected to outperform in the existing economic climate. All of RiverSource's strategies incorporate the use of both top-down and bottom-up analysis. The firm's equity strategies include: the RiverSource Contrarian 120/20 Strategy, the RiverSource Dividend Opportunity Strategy, the RiverSource Mid-Cap Growth Strategy, the RiverSource Mid-Cap Value Strategy, the RiverSource Opportunity Value Strategy, the RiverSource Value Strategy and the Seligman Small-Cap Value Strategy. Though not limited by sector, RiverSource tends to invest in the stocks of mid-cap and large-cap companies in the finance, electronic technology, technology services and health technology sectors. The firm maintains a low turnover rate. The RiverSource Contrarian 120/20 strategy's structure allows for focus on opportunities without style confinement. It is a short portfolio that seeks to achieve efficient risk management and increased informational efficiency through investments in ETFs and index/basket securities combined with a long portfolio that seeks to generate total return. The RiverSource Dividend Opportunity strategy employs a disciplined contrarian approach that employs collaborative analysis that incorporates intrinsic value and behavioral insights with disciplined risk management. The strategy seeks to provide competitive performance over the long-term. The RiverSource Mid-Cap Growth strategy seeks to achieve competitive risk-adjusted returns over full market cycles through investments in high-quality growth companies with solid fundamental strengths including proven management teams, sustainable franchises, earnings improvement, sufficient free cash flow and reasonable valuations. The RiverSource Mid-Cap Value strategy employs a disciplined contrarian approach that employs collaborative analysis that incorporates intrinsic value and behavioral insights and disciplined risk management. The strategy seeks to provide competitive performance over the long-term. The RiverSource Opportunity Value strategy employs a disciplined contrarian investment approach that focuses on investments in the stocks of large-cap companies. The strategy is based on a disciplined contrarian approach that employs collaborative analysis which incorporates intrinsic value and behavioral insights and disciplined risk management. The strategy seeks to provide competitive performance over the long-term. The RiverSource Value strategy employs a disciplined large-cap value contrarian investment approach that is based on collaborative analysis which incorporates intrinsic value and behavioral insights and disciplined risk management. The strategy seeks to provide competitive performance over the long-term. The Seligman Small-Cap Value strategy seeks to generate competitive returns over a 3 to 5 year time horizon through investments in undervalued companies with improving fundamentals and market-caps of $3 billion or less. RiverSources' fixed-income strategies include: the RiverSource Bank Loan Strategy, the RiverSource Core Fixed-Income Aggregate Strategy, the RiverSource Core Plus Fixed-Income Aggregate Strategy, the RiverSource Currency Alpha Absolute Return Strategy, the RiverSource Global Aggregate Fixed-Income Strategy, the RiverSource Global Government Fixed-Income Strategy, the RiverSource Global Inflation Protected Securities Strategy, the Institutional High Yield Fixed-Income Strategy, the RiverSource Investment Grade Corporate Fixed-Income Strategy and the RiverSource US Inflation Protected Securities Strategy. The RiverSource Bank Loan strategy invests in a broadly diversified portfolio that seeks to maximize returns and minimize default risk over the long-run. The RiverSource Core Fixed-Income Aggregate strategy seeks to produce consistent excess returns over a client's benchmark within a risk-managed framework that is consistent with the client's objectives. The RiverSource Core Plus Fixed-Income Aggregate strategy seeks to produce excess returns over a client's benchmark within a risk-managed framework that is consistent with the client's objectives through investments that include high yield, non-dollar and emerging markets opportunities. The RiverSource Currency Alpha Absolute Return strategy seeks to achieve positive absolute returns in excess of the return on cash, with a low correlation to traditional asset classes. The RiverSource Global Aggregate Fixed-Income strategy seeks to generate alpha in a risk-controlled framework by focusing on multiple and uncorrelated sources of active risk. The RiverSource Global Government Fixed-Income strategy seeks to generate alpha in a risk-controlled framework by focusing on multiple and uncorrelated sources of active risk, through investments that focus on global government and government-related securities. The RiverSource Global Inflation Protected Securities strategy seeks to provide positive risk-adjusted returns relative to the benchmark by focusing on duration management, yield curve and country selection across global markets. RiverSource's Institutional High Yield Fixed-Income strategy seeks strong and consistent risk-adjusted returns with a focus on generating alpha and actively managing downside risk. The RiverSource Investment Grade Corporate Fixed-Income strategy seeks credit opportunities in the investment grade corporate bond market that can be exploited to achieve attractive risk-adjusted returns. The strategy focuses on investments in securities with solid fundamental credit, a reasonable time horizon and the ability to withstand short-term volatility. The RiverSource US Inflation Protected Securities strategy seeks to provide positive risk-adjusted returns relative to the benchmark by focusing on duration management, yield curve and security selection in domestic markets. | Finance |
BB Biotech AG
 BB Biotech AG Financial ConglomeratesFinance Provides investment services for biotechnology sector | Finance |
American Express Asset Management International (UK)
 American Express Asset Management International (UK) Financial ConglomeratesFinance Provides financial payments, networking and travel services | Finance |
Putnam U.S. Holdings I LLC
 Putnam U.S. Holdings I LLC Investment ManagersFinance Provides asset management services | Finance |
Apellis Pharmaceuticals, Inc.
 Apellis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics and drug delivery technologies for addressing chronic inflammatory diseases | Health Technology |
Atea Pharmaceuticals, Inc.
 Atea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes antiviral therapeutics | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage structure based drug design company for cancer diseases | Health Technology |
Element Science, Inc.
 Element Science, Inc. Electronic Equipment/InstrumentsElectronic Technology Develops wearable cardioverter defibrillators | Electronic Technology |
Millennium Management LLC
 Millennium Management LLC Investment ManagersFinance Millennium Management employs a global multi-strategy investment approach, opportunistically engaging in a broad array of trading and investing strategies across a wide group of diversified managers. The firm prefers trading teams that produce small gains on winning days and smaller losses on losing days. They emphasize diversity in asset classes, industry sectors and geographic boundaries and invest in a variety of domestic and international equity and debt securities, currencies, futures, forwards, options and other instruments. | Finance |
Fudan University
 Fudan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bellevue Research, Inc.
 Bellevue Research, Inc. Investment ManagersFinance Provides investment research | Finance |
North Tide Capital LLC
 North Tide Capital LLC Investment ManagersFinance North Tide Capital aims to achieve superior risk-adjusted returns by investing substantially, but not solely, in the publicly traded common stock of companies in the healthcare industry. The firm performs in-depth analysis to determine a fair intrinsic value for various stocks within the healthcare universe, and as market prices fluctuate around that intrinsic value, they look for opportunities to profit. | Finance |
American Express Asset Management Group Inc. | |
Asterion LLC
 Asterion LLC Chemicals: SpecialtyProcess Industries Manufactures chemical finishing products | Process Industries |
BiVACOR, Inc.
 BiVACOR, Inc. Medical SpecialtiesHealth Technology Develops and manufactures medical devices | Health Technology |
Cormorant Asset Management LP
Cormorant Asset Management LP Investment ManagersFinance Cormorant’s Hedge Fund seeks superior risk-adjusted returns with low market correlation through a combination of long investment positions and short selling to achieve capital appreciation while attempting to preserve capital and mitigate risk through hedging activities. Most of the Hedge Funds’ assets are invested on a global basis in publicly traded equity securities in the healthcare and life science industries. The Private Equity Funds aim to generate significant long-term capital appreciation by creating or investing in innovative companies in the biotechnology and life sciences marketplace. The firm uses a fundamental, research-intensive approach that focuses primarily on scientific research to identify investment opportunities. | Finance |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Impresa Management LLC
 Impresa Management LLC Investment ManagersFinance F-Prime invests in companies located in Asia, Europe, North America and South America. The firm targets companies operating in the fields of life sciences, technology, healthtech & services and crypto sectors. It provides financing for seed, early and later stage transactions. | Finance |
Weill Cornell Graduate School of Medical Sciences
 Weill Cornell Graduate School of Medical Sciences Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atia Vision, Inc.
Atia Vision, Inc. Medical SpecialtiesHealth Technology Manufactures intraocular lens | Health Technology |
Kezar Life Sciences, Inc.
 Kezar Life Sciences, Inc. BiotechnologyHealth Technology Discovers and develops therapies targeting protein homeostasis | Health Technology |
Orionis Biosciences, Inc.
 Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Offers protein interaction platform with direct applications in the discovery of new therapeutics | Technology Services |
C4 Therapeutics, Inc.
 C4 Therapeutics, Inc. BiotechnologyHealth Technology Develops targeted protein degradation therapeutics for the treatment of cancer | Health Technology |
CRMA SPV LP
 CRMA SPV LP Finance/Rental/LeasingFinance Acts as a financing subsidiary/Special purpose entity | Finance |
Supira Medical, Inc.
 Supira Medical, Inc. Medical SpecialtiesHealth Technology Develops percutaneous ventricular assist devices | Health Technology |
Cormorant Asset Management LLC/Private Equity/
Cormorant Asset Management LLC/Private Equity/ Investment ManagersFinance Cormorant Asset Management/Private Equity/ invests in companies located in the United States. The firm targets companies operating in the fields of life-science and biotech. It provides financing for mezzanine and early stage capital requirements. | Finance |
Cormorant Private Healthcare Fund I LP
 Cormorant Private Healthcare Fund I LP Investment ManagersFinance Acts as Private Equity Fund | Finance |
Cormorant Private Healthcare Fund II LP
 Cormorant Private Healthcare Fund II LP Investment ManagersFinance Acts as Private Equity Fund | Finance |
Erasca, Inc.
 Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Tioga Cardiovascular, Inc.
 Tioga Cardiovascular, Inc. Medical SpecialtiesHealth Technology Manufactures valve replacement systems for mitral applications | Health Technology |
Myra Vision, Inc.
 Myra Vision, Inc. Medical SpecialtiesHealth Technology Manufactures ophthalmic surgical devices | Health Technology |
Adona Medical, Inc.
Adona Medical, Inc. Medical SpecialtiesHealth Technology Develops implantable cardiovascular devices | Health Technology |
Interius BioTherapeutics, Inc.
 Interius BioTherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops vivo CAR therapeutics | Health Technology |
Cormorant Private Healthcare Fund III LP
 Cormorant Private Healthcare Fund III LP Investment ManagersFinance Functions as a private equity fund | Finance |
Helix Acquisition Corp.
 Helix Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Helix Holdings LLC | |
Biomea Fusion, Inc.
 Biomea Fusion, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which engages in the discovery, development and commercialization of small molecules to treat patients with genetically defined cancers | Health Technology |
Blossomhill Therapeutics, Inc.
 Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for oncology and autoimmune diseases | Health Technology |
Graviton Bioscience Corp.
 Graviton Bioscience Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for the treatment of autoimmune, cancer, genetic, fibrotic and other serious diseases | Health Technology |
Chroma Medicine, Inc.
Chroma Medicine, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures genetic medicines | Health Technology |
Obvius Robotics, Inc.
 Obvius Robotics, Inc. Medical SpecialtiesHealth Technology Develops medical devices focused on central venous catheterization and vascular access | Health Technology |
Cormorant Private Healthcare Fund Iv LP
 Cormorant Private Healthcare Fund Iv LP Investment ManagersFinance Functions as a private equity fund | Finance |
Akura Medical, Inc.
Akura Medical, Inc. Medical SpecialtiesHealth Technology Develops next-generation thrombectomy devices | Health Technology |
Orionis Biosciences BV
Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Operates as a drug discovery and development biotechnology company | Health Technology |
Aleksia Therapeutics, Inc. | |
Nexo Therapeutics, Inc.
 Nexo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for cancer patients | Health Technology |
Cormorant Private Healthcare Fund V LP
 Cormorant Private Healthcare Fund V LP Investment ManagersFinance Functions as a private equity fund | Finance |
